ClinicalTrials.gg
CompletedNCT02735863Updated Sep 19, 2024Results posted

ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment

A Phase 2 interventional study of ABX464 and Placebo in HIV Infection, sponsored by Abivax S.A.. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies in HIV Infections with a site in Belgium — 3 open to participants now, 8 under way, 3 of them phase 3. HIV Infections · Belgium.

Enrollment
73rd of 80
30 · median 439
Started
2016
with 2 others
Phase 2
11 of 97
1 open now
Registered
71st of 97
by date

Among the 97 studies in HIV Infections with a site in Belgium, this one is the 73rd largest by enrollment of the 80 interventional ones that give a count, is one of 3 that started in 2016, is one of 11 in phase 2, and was the 71st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

3 of the 97 studies in HIV Infections with a site in Belgium are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in HIV Infections with a site in Belgium, or all of them as a file.
02

Study summary

This study is a placebo-controlled study aimed at assessing the safety of ABX464 administered at 50 mg and 150 mg o.d. versus placebo in HIV infected patients who are treated with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI).

Read the detailed description

This study is a placebo-controlled study aimed at assessing the safety of ABX464 administered at 50 mg o.d. and 150 mg versus placebo in HIV infected patients who are treated with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI). Eligible patients should be treated with darunavir + ritonavir or darunavir + cobicistat as monotherapy for at least 8 weeks prior to baseline. Patients should be fully suppressed (\< 50 copies/mL) at least during the last 6 months prior to enrolment.

Upon screening visit, eligible patients will continue DRV/RTV or DRV/COBI single regimen given respectively at 800 mg of darunavir with 100 mg of ritonavir or 150 mg of cobicistat once a day with food in the morning.

At Day 0, study drug (ABX464 or its matching placebo) will be added on top of this background therapy for the next 28 days. ABX464 or its matching placebo will be given once a day at 50 mg or 150 mg.

At day 29, DRV/RTV or DRV/COBI and ABX464 or its matching placebo (i.e. all treatments) will be stopped. The viral load will be monitored twice a week during the first three weeks and weekly during the next weeks. In case of Viral Rebound (VR; defined below), ART will be resumed.

A 3:1 randomization ratio will be applied meaning that, per treatment block, 3 patients will receive ABX464 on top of DRV/RTV or DRV/COBI and 1 patient will receive placebo on top of DRV/RTV or DRV/COBI.

Dose limiting toxicity (DLT) is defined as a grade 3 or higher adverse event as defined by the "Division of AIDS table for grading the severity of adult and pediatric adverse events" (including signs/symptoms, lab toxicities and/or clinical events) considered by the Data Safety Monitoring Board as probably or definitely related to study treatment.

If more than 2 DLTs occur during the treatment period of the first four treated patients, then the enrolment of additional patients will be stopped. In addition, in case of a life threatening (grade 4) adverse reaction enrolment and treatment of ongoing patients will be immediately discontinued. In both cases, enrolment will only be resumed upon the decision of the sponsor if the Data Safety Monitoring Board can conclude that the causality of the event was unrelated or unlikely related to study treatment.

Thorough pharmacokinetics analysis will be performed to characterize potential drug-drug interactions between ABX464 and DRV/RTV-COBI.

03

Conditions studied

  • HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients infected with ;
  • Patients with HIV plasma viral load ≤ 50 copies mL-1 during the 6 months prior to screening with a maximum of 2 blips during this period;
  • Patients treated by DRV/RTV or DRV/COBI as a monotherapy for at least 8 weeks prior to baseline;
  • Patients' HIV plasma viral load ≤100,000 copies mL-1 at any time (apart from primary infection if recorded);
  • Patients' ≥ 250 cells per mm3 at any time since diagnosis;
  • Patients with CD4+ T cells count ≥ 600 cells per mm3 at screening;
  • Man or woman aged 18-65 years;

Exclusion criteria

Exclusion Criteria:

  • Patient displaying any protease inhibitor resistance mutation as listed in the current version of the HIV drug resistance database (Stanford University);
  • Patient having had previously a viral load ≥ 500 copies mL-1 confirmed by a second measure since the initiation of the current ART;
  • History of an AIDS-defining clinical illness;
  • Concomitant AIDS-related opportunistic infection;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    ABX464

    Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)

    Drug: ABX464

  • Placebo comparator
    ABX464 Matching placebo

    Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)

    Drug: Placebo

Interventions

  • DrugABX464

    50 mg or 150mg once daily for 28 days

  • DrugPlacebo

    ABX464 matching placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Patients who had received at least one dose of the study drug, and who had at least one baseline value. An AE was classified as a TEAE if it started, or increased in severity, on or after the first date and time of medication dosing (from Day 1 up to Day 28). Any AE which occurred after Day 28 was classified as post-treatment-emergent. Events were graded according to the "Division of AIDS table for grading the severity of adult and pediatric adverse events" (Version 2.0 November 2014).

    Time frame: Up to 4 months

Secondary outcomes

  1. Time to Viral Rebound

    Time To Viral Rebound is defined as the time between treatment stop (i.e. day 29) and viral rebound detection

    Time frame: Up to 3 months

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneABX464 50mgABX464 150mgABX464 Matching Placebo
Started6168
Completed5147
Not completed121

Outcome measures

PrimaryNumber of Participants With Adverse Events

Patients who had received at least one dose of the study drug, and who had at least one baseline value. An AE was classified as a TEAE if it started, or increased in severity, on or after the first date and time of medication dosing (from Day 1 up to Day 28). Any AE which occurred after Day 28 was classified as post-treatment-emergent. Events were graded according to the "Division of AIDS table for grading the severity of adult and pediatric adverse events" (Version 2.0 November 2014).

Time frame:
Up to 4 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsABX464 50mgABX464 150mgABX464 Matching Placebo
Any AE5157
Any TEAE4153
Any post-TEAE464
Any serious AE001
Any severe AE010
AE leading to death000
SecondaryTime to Viral Rebound

Time To Viral Rebound is defined as the time between treatment stop (i.e. day 29) and viral rebound detection

Time frame:
Up to 3 months
Reported as:
Mean · days
Time to Viral Rebound
daysABX464 50mgABX464 150mgABX464 Matching Placebo
Time to Viral Rebound17.2 ± 3.414.4 ± 7.414.4 ± 7.3
Statistical analysis
  • ABX464 50mg vs ABX464 150mg vs ABX464 Matching Placebo · Log Rank · p = 0.5352

Adverse events

Collected over Up to 4 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABX464 50mg0/6 (0%)0/6 (0%)5/6 (83.3%)
ABX464 150mg0/16 (0%)1/16 (6.3%)15/16 (93.8%)
ABX464 Matching Placebo0/8 (0%)1/8 (12.5%)7/8 (87.5%)
Most frequent serious events
Most frequent serious events
EventABX464 50mgABX464 150mgABX464 Matching Placebo
vagal faintnessNervous system disorders0/60/161/8
FatigueGeneral disorders0/61/160/8
Most frequent other events
Showing 10 of 40
Most frequent other events
EventABX464 50mgABX464 150mgABX464 Matching Placebo
HeadacheNervous system disorders2/65/160/8
Back PainMusculoskeletal and connective tissue disorders0/65/160/8
Abdominal Pain UpperGastrointestinal disorders0/64/160/8
NasopharyngitisInfections and infestations0/60/162/8
Abdominal PainGastrointestinal disorders0/63/160/8
DiarrheaGastrointestinal disorders1/63/160/8
FatigueGeneral disorders0/63/160/8
Influenza Like IllnessGeneral disorders1/61/160/8
ContusionInjury, poisoning and procedural complications1/60/160/8
ScarInjury, poisoning and procedural complications1/60/160/8

Baseline characteristics

Patients who had received at least one dose of the study drug, and who had at least one baseline value.

Age, Categorical
Age, Categorical(Participants)ABX464 50mgABX464 150mgABX464 Matching PlaceboTotal
<=18 years0000
Between 18 and 65 years616830
>=65 years0000
Age, Continuous
Age, Continuous(years)ABX464 50mgABX464 150mgABX464 Matching PlaceboTotal
Mean45.2 ± 3.538.4 ± 10.448.3 ± 8.542.4 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)ABX464 50mgABX464 150mgABX464 Matching PlaceboTotal
Female0101
Male615829
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABX464 50mgABX464 150mgABX464 Matching PlaceboTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American0202
White614727
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)ABX464 50mgABX464 150mgABX464 Matching PlaceboTotal
Belgium310417
France0112
Spain35311
08

Study locations

8 sites
  • C.H.U. Saint-Pierre
    Bruxelles, 1000, Belgium
  • Ghent University Hospital
    Ghent, 9000, Belgium
  • CHU Sart Tilman
    Liège, 4000, Belgium
  • Hôpital de la Croix Rousse
    Lyon, 69004, France
  • CHU de Montpellier - Hôpital Gui de Chauliac
    Montpellier, 34 295, France
  • Hospital Clinic
    Barcelona, 08036, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Hospital Universitari Germans Trias i Pujo
    Barcelona, 08916, Spain
09

References and documents

Publications

  • Rutsaert S, Steens JM, Gineste P, Cole B, Kint S, Barrett PN, Tazi J, Scherrer D, Ehrlich HJ, Vandekerckhove L. Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. J Virus Erad. 2019 Jan 1;5(1):10-22. doi: 10.1016/S2055-6640(20)30273-9. PubMed 30800421 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Aug 2017 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2024, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2016
First posted
Apr 13, 2016
Start
May 2016
Primary completionActual
Aug 30, 2017
CompletionActual
Jan 11, 2018
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02735863
Lead sponsor
Abivax S.A.
Responsible party
Sponsor
First posted
Apr 13, 2016
Start date
May 2016
Primary completion
Aug 30, 2017
Completion
Jan 11, 2018
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion